Business Context and Reporting Period
This Form 8-K is a current report filed by Oncocyte Corporation (not Insight Molecular Diagnostics Inc.) on October 27, 2021. The registrant is incorporated in California and trades on The Nasdaq Stock Market under the symbol OCX. The filing reports a specific corporate event rather than periodic financial results.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. As an 8-K reporting a specific event, the document does not provide a clear value for any financial metrics.
Material Changes
The material event reported is the issuance of U.S. Patent No. 11,155,872 on October 27, 2021. The patent covers a digital polymerase chain reaction (dPCR) technique for the molecular detection of solid organ allograft rejection. This represents an expansion of the company's intellectual property portfolio.
Guidance, Outlook, and Risks
The filing includes standard forward-looking statement disclaimers, noting that actual results may differ materially from anticipated results due to risks detailed in the company's Form 10-K. No specific financial guidance, management commentary on future performance, or new contingencies were disclosed in this report.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for details on the patent's commercial potential.
- Confirm the company name is Oncocyte Corporation (OCX), as the input metadata referenced a different entity.
- Review the company's most recent Form 10-K or 10-Q for current financial health, as this 8-K contains no financial data.
- Assess the strategic importance of the dPCR patent for solid organ allograft rejection within the company's broader product pipeline.